Table 1.
Characteristics and laboratory data of diabetic db/db mice that received a normal diet containing the indicated treatments.
| Control | Ipragliflozin | Alogliptin | Combination | |
|---|---|---|---|---|
| Number | 8 | 8 | 8 | 7 |
| Final body weight (g) | 49.6 ± 0.4 | 46.5 ± 1.0 | 48.5 ± 0.4 | 46.8 ± 0.7 |
| Food intake (g/day) | 4.5 ± 0.3 | 4.8 ± 0.4 | 4.2 ± 0.2 | 4.9 ± 0.3 |
| Water intake (mL/day) | 4.2 ± 0.2 | 9.6 ± 1.0a,c | 4.4 ± 0.3 | 9.9 ± 0.9a,c |
| Urine volume (mL/day) | 7.6 ± 0.3 | 12.7 ± 1.0a,c | 8.1 ± 0.4 | 13.8 ± 0.9a,c |
| SBP (mmHg) | 109 ± 2 | 104 ± 4 | 107 ± 3 | 105 ± 2 |
| Pulse (/min) | 587 ± 36 | 655 ± 42 | 570 ± 60 | 672 ± 29 |
| Glucose (mg/dL) | 424 ± 37 | 213 ± 32a | 231 ± 23a | 157 ± 13a,c |
| HbA1c (%) | 8.1 ± 0.1 | 6.7 ± 0.2a | 7.4 ± 0.3a,b | 6.6 ± 0.1a,c |
| Insulin (ng/mL) | 5.19 ± 0.42 | 5.32 ± 0.89 | 8.20 ± 0.96a,b | 9.56 ± 1.02a,b |
| Total-C (mg/dL) | 146 ± 12 | 167 ± 19 | 147 ± 13 | 181 ± 13 |
| HDL-C (mg/dL) | 62 ± 5 | 65 ± 7 | 64 ± 7 | 86 ± 14 |
| Triglyceride (mg/dL) | 72 ± 9 | 61 ± 7 | 69 ± 13 | 65 ± 13 |
| Active GLP-1 (pmol/L) | 2.6 ± 0.3 | 2.7 ± 0.3 | 10.3 ± 2.2a,b | 7.4 ± 1.1a,b |
| Total GIP (pmol/L) | 49 ± 10 | 56 ± 14 | 106 ± 19a,b | 123 ± 29a,b |
The values show mean ± SEM. Ipragliflozin, sodium-glucose cotransporter 2 inhibitor; alogliptin, dipeptidyl peptidase-4 inhibitor; SBP, systolic blood pressure; HbA1c, hemoglobin A1c; Total-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; GLP-1, glucagon like peptide-1; GIP, glucose-dependent insulinotropic polypeptide. ap < 0.05 versus control; bp < 0.05 versus ipragliflozin; cp < 0.05 versus alogliptin.